Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia [0.03%]
免疫疗法联合治疗可增强急性髓系白血病患者T细胞对白血病细胞及白血病干细胞的特异性免疫应答
Jochen Greiner,Patrick J Schuler,Hubert Schrezenmeier et al.
Jochen Greiner et al.
Immunotherapeutic approaches have become increasingly important in cancer therapy, including for patients with acute myeloid leukemia (AML). Despite being shown to be effective in the context of stem cell transplants for almost 50 years, fu...
CRISPR/Cas9-mediated t(4;11) translocation in human hematopoietic stem/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage [0.03%]
CRISPR/Cas9诱导的人源造血干/祖细胞t(4;11)易位可分化为髓系或淋巴系白血病细胞
T Benz,P Larghero,C Meyer et al.
T Benz et al.
The chromosomal translocation t(4;11)(q21;q23) is frequently diagnosed in KMT2A-r Acute Leukemia patients. Although we understand much about the function of both wildtype KMT2A and AFF1 multiprotein complexes, little is known about the mole...
Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study [0.03%]
高危急性淋巴细胞白血病首次缓解期强化化疗的疗效：来自NOPHO ALL2008研究的结果
Atte Nikkilä,Olli Lohi,Jonas Abrahamsson et al.
Atte Nikkilä et al.
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients [0.03%]
欧洲4978例强化治疗AML患者中与骨髓增生异常相关基因突变的不同预后影响
Marius Bill,Jan-Niklas Eckardt,Konstanze Döhner et al.
Marius Bill et al.
In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact ...
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study [0.03%]
基于First-MIND I期研究的ctDNA变化证明了tafasitamab+R-CHOP联合或不联合来那度胺治疗弥漫性大B细胞淋巴瘤可快速起效并预测预后
Mouhamad Khouja,Britta Kehden,Derek Blair et al.
Mouhamad Khouja et al.
The firstMIND trial (NCT04134936) evaluated the safety and efficacy of adding lenalidomide to R-CHOP+tafasitamab in the first-line treatment settings of patients with diffuse large B-cell lymphoma. To address response dynamics and the impac...
Structure-based prediction reveals a difference in the binding mode of anti-BCMA antibodies to BCMA and soluble BCMA [0.03%]
基于结构的预测揭示了抗BCMA抗体与BCMA及可溶性BCMA结合模式的不同
Jiro Kikuchi,Naoki Osada,Sae Matsuoka et al.
Jiro Kikuchi et al.
Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia [0.03%]
题图：miR-10a作为MDM2抑制治疗急性髓系白血病的治疗靶点和预测生物标志物的纠正意见
Thi Thanh Vu,Friedrich Stölzel,Kristy W Wang et al.
Thi Thanh Vu et al.
Published Erratum
Leukemia. 2025 Oct 17. DOI:10.1038/s41375-025-02788-z 2025
DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits [0.03%]
急性淋巴细胞白血病幸存者迟发型神经认知缺陷的DNA甲基化变化
Sarah J Goodman,Darci T Butcher,Sharon L Guger et al.
Sarah J Goodman et al.
OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure [0.03%]
OGG1活化可增强allo-SCT和T细胞衔接器暴露后T细胞的氧化应激抵抗能力
D Saul,C Lischer,H Bruns et al.
D Saul et al.
Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission [0.03%]
出版更正：通过抑制线粒体分裂减弱 rho 关联激酶 1（ROCK1）可促进人类造血干细胞扩增
Xuepeng Wang,Baskar Ramdas,Ramesh Kumar et al.
Xuepeng Wang et al.
Published Erratum
Leukemia. 2025 Oct 13. DOI:10.1038/s41375-025-02786-1 2025